{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-unidentified-cause/prescribing-information/h2-receptor-antagonists/","result":{"pageContext":{"chapter":{"id":"a51b3918-0bed-5c45-887b-a5d3e5fd3031","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists","depth":2,"htmlHeader":"<!-- begin field 4daad40d-e3d7-4fc8-a25c-c3e0ac4b6c59 --><h2>H2-receptor antagonists</h2><!-- end field 4daad40d-e3d7-4fc8-a25c-c3e0ac4b6c59 -->","summary":"","htmlStringContent":"<!-- begin item 6806240e-a433-4054-906e-5253b3e99e66 --><!-- end item 6806240e-a433-4054-906e-5253b3e99e66 -->","topic":{"id":"f89632d0-8e52-59da-bd63-555a73aa134f","topicId":"ac596995-c452-4bf5-81bf-0aea66eca309","topicName":"Dyspepsia - unidentified cause","slug":"dyspepsia-unidentified-cause","lastRevised":"Last revised in October 2018","chapters":[{"id":"9fdd530d-f12b-5642-954b-6284524a3fdb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4ac2b712-5571-56ca-9ac4-25c9e354a821","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16fcbe75-c057-5b25-8039-9145eb897f12","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"be6e1eb9-7eb4-54b8-980d-7a18a90127c3","slug":"changes","fullItemName":"Changes"},{"id":"8eb7dbc2-40da-5433-b290-44902a364d61","slug":"update","fullItemName":"Update"}]},{"id":"a44ffd66-34ee-565e-8b89-d09f62dd9656","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ad917944-2a8c-561c-ba7d-5e5c7ea860e4","slug":"goals","fullItemName":"Goals"},{"id":"cbb4bad0-1dbe-5c62-9adc-bb1a65fe6381","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"54d592f8-f244-5cc8-aed5-81cb136af042","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca8a0b2-46c5-52c2-a05d-1ae84806cefd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5e33c66-dee5-57d8-9eff-828ad855e204","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"eff9b41a-cac2-5b9a-8614-2486d8206ffd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4dfc51d9-1416-5432-bc80-019f5708238c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec8766af-6b0a-5a4d-8897-2e3ba2af658d","slug":"definition","fullItemName":"Definition"},{"id":"e1cbef45-8ac7-5376-a1d2-c5d0a2cc924b","slug":"causes","fullItemName":"Causes"},{"id":"c7487dda-a4e1-5d9e-bc96-e583302af12c","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"0eb82dd3-e433-5b8e-a8d9-46987aab8940","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2acef31-cf6d-5e3e-b2e0-99bc02684183","slug":"assessment","fullItemName":"Assessment"},{"id":"86ebd63c-3596-5ac0-9cd3-4a312bb2d7e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f244ecd9-294a-5fa3-9b22-a2e8f2ae408c","fullItemName":"Management","slug":"management","subChapters":[{"id":"bafb1a12-7cf3-5c6c-921a-03d86efd995d","slug":"dyspepsia-unidentified-cause","fullItemName":"Scenario: Dyspepsia - unidentified cause"}]},{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2978bf31-384a-5964-bba7-5ca72e2a700a","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"a51b3918-0bed-5c45-887b-a5d3e5fd3031","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"8579e41d-876a-5f82-9cb8-04675dce1bb3","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"d41b619e-ef9e-59b6-876b-0b3d52f0884a","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"9ea259a4-6c7f-524f-8866-6164a9696c25","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"640d4b46-3f9c-5cef-aeda-9a374a03fae8","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"fe5b2b68-8d84-5867-bc39-c63cbcd815f8","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"0857fa25-e261-5ecd-b851-fbe52518072d","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"210b1a7b-a0e0-558a-acbe-539f538e840d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0e0cffca-8140-5660-bd87-d4288485522f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4726f06d-25b6-56d1-83c0-3d729c2bb571","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"301b4d9b-8d13-5cc1-8e9a-f8f68c4fa019","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5e963a22-e16a-5e4a-b7a9-072decaccaa1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1d047d4-3011-5ca0-955c-b366ab2a9fb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cd5de0cc-ba55-5ad9-b09b-3025cc68334c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc0ebb19-4869-5b31-8bcf-f0b6e5af54db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"23e4fd87-3671-5603-b04f-500748acb745","slug":"choice-of-h2-receptor-antagonist","fullItemName":"Choice of H2-receptor antagonist","depth":3,"htmlHeader":"<!-- begin field 40c0f5f4-b811-4776-b7e8-f3c32d73cb96 --><h3>Choice of H2-receptor antagonist</h3><!-- end field 40c0f5f4-b811-4776-b7e8-f3c32d73cb96 -->","summary":"","htmlStringContent":"<!-- begin item be89047b-9c0f-4235-b875-b19339d31014 --><!-- begin field a4e19e04-e3e9-438b-897c-de50c52c1e09 --><ul><li>Ranitidine is a histamine (H<sub>2</sub>)-receptor antagonist (H<sub>2</sub>RA) which is licensed for the management of people with persistent dyspepsia symptoms.<ul><li>The usual treatment dose is 150 mg twice a day (or 300 mg at night).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field a4e19e04-e3e9-438b-897c-de50c52c1e09 --><!-- end item be89047b-9c0f-4235-b875-b19339d31014 -->","subChapters":[]},{"id":"94733c89-1b23-50d2-a155-3005d4b8420a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 98fc7f3c-c3d8-4528-99ae-a77c012c8c12 --><h3>Contraindications and cautions</h3><!-- end field 98fc7f3c-c3d8-4528-99ae-a77c012c8c12 -->","summary":"","htmlStringContent":"<!-- begin item 813806a5-f220-4c36-a093-a77c012c8679 --><!-- begin field b9672194-add4-4e8d-8842-a77c012c8c12 --><ul><li><strong>Histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as H<sub>2</sub>RAs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking an H<sub>2</sub>RA and subsequently needs an endoscopy, the H<sub>2</sub>RA should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>H<sub>2</sub>RAs should be prescribed with caution in people with renal impairment:</strong><ul><li>For ranitidine, if the estimated glomerular filtration rate (eGFR) is less than 50 mL/minute/1.73m<sup>2</sup>, prescribe half the normal daily dose.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field b9672194-add4-4e8d-8842-a77c012c8c12 --><!-- end item 813806a5-f220-4c36-a093-a77c012c8679 -->","subChapters":[]},{"id":"c95161f6-93fa-55f4-92fb-e8169ec79be1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 26b9cc4a-3082-48e9-b587-a77c012cc9c9 --><h3>Adverse effects</h3><!-- end field 26b9cc4a-3082-48e9-b587-a77c012cc9c9 -->","summary":"","htmlStringContent":"<!-- begin item 5fa9ceb6-51dd-42be-959f-a77c012cb1e7 --><!-- begin field d5a77cdd-ae63-4ff3-bbf5-a77c012cc9c9 --><ul><li>Adverse effects of histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) are uncommon and include diarrhoea, headache, dizziness, rash, and tiredness.</li><li>Rare or very rare adverse effects include hepatitis, cholestatic jaundice, bradycardia, depression, confusion, hallucinations, leucopenia, thrombocytopenia, and pancytopenia, arthralgia, and myalgia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field d5a77cdd-ae63-4ff3-bbf5-a77c012cc9c9 --><!-- end item 5fa9ceb6-51dd-42be-959f-a77c012cb1e7 -->","subChapters":[]},{"id":"d49acb7c-e82c-5827-bd6f-a65be6f33ad5","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 210f61f6-b591-4baa-b03a-a77c012ce4f9 --><h3>Drug interactions</h3><!-- end field 210f61f6-b591-4baa-b03a-a77c012ce4f9 -->","summary":"","htmlStringContent":"<!-- begin item 15e649c0-3309-44af-afa9-a77c012ce353 --><!-- begin field 7044f880-c1aa-4b9f-96b4-a77c012ce4f9 --><ul><li><strong>Possible drug interactions with histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) include:</strong><ul><li>Azole antifungals — because of decreased gastric acidity, the absorption of ketoconazole or itraconazole may be reduced if taken with an H<sub>2</sub>RA.</li><li>Protease inhibitors — atazanavir plasma levels are reduced by H<sub>2</sub>RAs. The manufacturer of atazanavir advises adjustment of the doses of both drugs when given with an H<sub>2</sub>RA. Seek specialist advice as needed.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field 7044f880-c1aa-4b9f-96b4-a77c012ce4f9 --><!-- end item 15e649c0-3309-44af-afa9-a77c012ce353 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}